All In Biotech

Drug Trial Radar · NCT06341894

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer

Last checked: Nov 19, 2026Latest source record: Apr 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,163

Planned (sponsor's estimate)

Start

Nov 17, 2023

Primary completion

Jun 2027

Study completion Jun 2029

Sponsor

Sponsor type
Academic, hospital or other
First posted
Apr 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigator conduct a phase II multi-center, open-label trial to evaluate efficacy and safety of dalpiciclib with endocrine therapy as adjuvant treatment in patients with medium /high risk hormone receptor-positive, HER2-negative Early Breast Cancer.

Conditions

  • Early Breast Cancer

Interventions

  • DalpiciclibDrug

    CDK4/6 inhibitor dalpiciclib, 100mg orally qd

  • Endocrine therapyDrug

    Fulvestrant/AI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. invasive Disease-free Survival (iDFS)Time frame: From enrollment until time of events up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.